Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.69 |
| ▸ | AURKA | O14965 | 14/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
| ▸ | YES1 | P07947 | 2/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3803679 | 0.99 | SRC (0.67) | SRCAURKAAURKB | |
| SCHEMBL3803684 | 0.99 | SRC (0.67) | SRCAURKAAURKB | |
| SCHEMBL12792854 | 0.95 | AURKA (0.66) | SRCAURKAAURKBPDGFRBKDR | |
| SCHEMBL3796496 | 0.93 | AURKA (0.68) | SRCAURKAAURKBPDGFRBKDR | |
| SCHEMBL3796504 | 0.93 | AURKA (0.68) | SRCAURKAAURKBPDGFRBKDR | |
| SCHEMBL3796810 | 0.87 | AURKA (0.82) | AURKAAURKBPDGFRBKDRFGFR1 | |
| SCHEMBL3796807 | 0.87 | AURKA (0.82) | AURKAAURKBPDGFRBKDRFGFR1 | |
| SCHEMBL3794034 | 0.86 | AURKA (0.80) | SRCAURKAAURKBPDGFRBKDR | |
| SCHEMBL3794029 | 0.86 | AURKA (0.80) | SRCAURKAAURKBPDGFRBKDR | |
| SCHEMBL3802814 | 0.86 | AURKA (0.69) | AURKAAURKBPDGFRBKDRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897602-B2 | Indolinone compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-03-01 | — | — | US | disclosed |
| US-7897602-B2 | Indolinone compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-03-01 | — | — | US | disclosed |
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2010-07-15 | — | — | US | disclosed |
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | CDK2, MAP3K19, MAP3K20 | SRC 394/4885AURKA 96/4885AURKB 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.